https://de.marketscreener.com/kurs/aktie/RECCE-PHARMACEUTICALS-LTD-24446338/news/Recce-Pharmaceuticals-schlie-t-Dosierung-in-klinischer-Phase-I-II-Studie-mit-Recce-327-gegen-Harn-44942624/?utm_source=telegram&utm_medium=social&utm_campaign=share